OCGN Ocugen Inc

0.00 (0.0%)
Pre Market
Last Updated: 07:00:04
Delayed by 15 minutes

Register Free for Streaming Quotes & Tools

Register for Free to get streaming quotes, interactive charts, trades, portfolio, live options flow and more.


Draw Mode:

Volume 3,287
Bid Price 0.405
Ask Price 0.4125
News -
Day High


52 Week Range


Day Low
Company Name Stock Ticker Symbol Market Type
Ocugen Inc OCGN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 0.405 07:00:04
Open Price Low Price High Price Close Price Prev Close
Trades Volume Avg Volume 52 Week Range
5 3,287 - 0.39 - 1.975
Last Trade Time Type Quantity Stock Price Currency
07:00:03 16 $ 0.408 USD

Ocugen Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
103.88M 256.49M - 0 -81.35M -0.32 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Ocugen News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No OCGN Message Board. Create One! See More Posts on OCGN Message Board See More Message Board Posts

Historical OCGN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.39990.42140.3980.40370221,100,0030.00511.28%
1 Month0.43060.45250.390.41604041,934,762-0.0256-5.95%
3 Months0.54650.6220.390.51342593,454,316-0.1415-25.89%
6 Months0.8520.89850.390.57106935,591,964-0.447-52.46%
1 Year1.941.9750.390.93481125,626,414-1.54-79.12%
3 Years0.3018.770.25016.6722,013,6680.10535.0%
5 Years3.2418.770.175.6519,626,829-2.84-87.5%

Ocugen Description

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug one to many and novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. The company is co-developing Bharat Biotech's COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets.